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ABSTRACT
Objective Charcot-Marie Tooth disease (CMT) forms a
clinically and genetically heterogeneous group of
disorders. Although a number of disease genes have
been identified for CMT, the gene discovery for some
complex form of CMT has lagged behind. The
association of neuropathy and optic atrophy (also known
as CMT type 6) has been described with
autosomaldominant, recessive and X-linked modes of
inheritance. Mutations in Mitofusin 2 have been found
to cause dominant forms of CMT6.
Phosphoribosylpyrophosphate synthetase-I mutations
cause X-linked CMT6, but until now, mutations in the
recessive forms of disease have never been identified.
Methods We here describe a family with three
affected individuals who inherited in an autosomal
recessive fashion a childhood onset neuropathy and optic
atrophy. Using homozygosity mapping in the family and
exome sequencing in two affected individuals we
identified a novel protein-truncating mutation in the
C12orf65 gene, which encodes for a protein involved in
mitochondrial translation. Using a variety of methods we
investigated the possibility of mitochondrial impairment
in the patients cell lines.
Results We described a large consanguineous family
with neuropathy and optic atrophy carrying a loss of
function mutation in the C12orf65 gene. We report
mitochondrial impairment in the patients cell lines,
followed by multiple lines of evidence which include
decrease of complex V activity and stability (blue native
gel assay), decrease in mitochondrial respiration rate and
reduction of mitochondrial membrane potential.
Conclusions This work describes a mutation in the
C12orf65 gene that causes recessive form of CMT6 and
confirms the role of mitochondrial dysfunction in this
complex axonal neuropathy.
INTRODUCTION
Inherited neuropathies are the most common
genetic neurological disorders and affect ∼1 in
2500 individuals.1 Charcot–Marie Tooth (CMT)
includes a group of hereditary disorders in which
motor and sensory neuropathy is the sole or
primary part of the disease. CMT is traditionally
classified into two types based on electrophysio-
logical and neuropathological criteria, where
CMT1 defined as ‘demyelinating’ and CMT2 as
‘axonal’.2 CMT can be associated with a variety of
additional clinical features. The association
between hereditary motor and sensory neuropathy
and optic atrophy, also known as CMT6 (OMIM
#601152), has been reported in families with dif-
ferent modes of inheritance, comprising over 50
cases.3–8 The clinical manifestations of CMT6
consist of distal muscle weakness and wasting start-
ing in the lower limb with reduced reflexes and
glove and stocking sensory loss. There is progres-
sive visual acuity loss due to optic atrophy, eventu-
ally leading to blindness. The age at onset is usually
in childhood for the neuropathy and in the second
decade for the optic atrophy.
Autosomal dominant CMT6 has previously been
found to harbour mutations in the Mitofusin 2
(MFN2) gene.9 X-linked recessive mutations have
been identified in the phosphoribosylpyropho-
sphate synthetase I (PRPS1) gene in CMT6 fam-
ilies.10 Conversely, no genetic cause for the
autosomal-recessive forms of CMT6 has been iden-
tified until the work described here, where we iden-
tify a novel mutation in the C12orf65 gene and
then characterise this mitochondrial protein in
CMT6.
METHODS
Samples
DNA samples from multiple individuals in a large
Indian family with CMT6 were collected at the
Royal Free Hospital, London. An additional 93
probands affected by complex axonal neuropathy
(axonal neuropathy plus one of the following:
optic atrophy, retinitis pigmentosa, psychomotor
retardation, cerebellar ataxia or pyramidal signs)
were collected at the National Hospital for
Neurology and Neurosurgery (NHNN), London.
All patients were negative for known mutations in
the following genes MFN2, MPZ, GJ1B, BSCL2
and NEFL. Additional 90 samples with axonal
neuropathy and evidence of mitochondrial impair-
ment on muscle biopsy were collected from the
neurometabolic unit at the NHNN. Genomic DNA
was purified from peripheral blood cells using
standard procedures.
Nerve biopsy
The nerve biopsy soon after the surgical removal
was immersed in a fixative for overnight containing
3% buffered glutaraldehyde and 0.2M sodium
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cacodylate buffer. Then, specimens were cut with razor in 1–
2 mm thick pieces and osmicated in secondary fixative—
osmium tetroxide. After fixation, the specimens were impreg-
nated into epoxy resin from which semithin (∼1 m) sections or
ultrathin (∼70 nm) sections were cut and put on glass slides or
grids, respectively. Semithin sections were stained either with
Methylene blue-Azure A and basic fuchsin or Toluidine blue
and examined by light microscopy on various magnifications.
Ultrathin (∼70 nm) sections were stained with uranyl acetate/
lead citrate and examined by electron microscopy on various
magnifications.
Single Nucleotide Polymorphism genotyping and
autozygosity mapping
Genome-wide SNP genotyping was performed at National
Institute of Health (NIH) (Bethesda, USA). Each individual was
assayed on a Illumina HumanHap300 BeadChip, yielding
approximately 317 000 SNPs. Samples were processed, hybri-
dised and scanned following the instructions of the manufac-
turer. Clustering, normalisation and genotype calls were
performed using the GenomeStudio 2010.3 Genotyping
Module (Illumina). Regions of shared homozygosity that segre-
gated with disease were visually identified using the Illumina
Genome Viewer tool within the BeadStudio suite.
Whole-exome sequencing was carried out at NIH (Bethesda,
USA). Nimblegen SeqCap EZ Exome (in solution capture) Kit
was used for the exome capture. Sequencing was performed on
a Genome Analyzer IIx, according to the manufacturer’s instruc-
tion. Raw sequencing reads were aligned to the hg18 build of
the reference genome using the software Novoalign. Calling was
performed using Samtools V.0.18 and the resulting calls were
annotated using ANNOVAR.
Mutation validation and screening in the additional cohorts
Primers for PCR amplification were designed by Generunner
(http://www.generunner.net/). After PCR amplification, coding
regions and exon–intron junctions of C12orf65 gene were
sequenced by Sanger’s sequencing, using the Big Dye
Terminator Cycle Sequencing Kit V3 (Applied Biosystems,
Foster City, California, USA) and analysed by a 3130 Genetic
Analyser sequencing machine (Applied Biosystems). Sequences
were examined in silico for mutations by Sequencher software
4.9 (Gene Codes Corporation, Ann Arbor, Michigan, USA).
Lymphoblast cell cultures
Lymphoblast cells were obtained from Case 1 and two
unaffected relative carriers. Lymphoblastoid cell lines were
established by Epstein–Barr virus transformation of lymphocytes
isolated from peripheral blood. Cell lines were stored at the
European Collection of Cell Cultures. Informed consent was
obtained for all samples. Patient and control lymphoblasts were
thawed and maintained in culture in modified RPMI-1640
medium containing 300 mg/L L-Glutamine and HEPES
(Invitrogen) supplemented with 10% heat-inactivated Fetal
Bovine Serum (FBS) (Invitrogen) at 37°C and 5% CO2. Fresh
medium was added every 3 days and cultures were expanded
accordingly.
Transcript analyses
Purification of total RNA was performed using the Qiagen
miRNeasy Mini Kit, Hilden, Germany (catalogue #217004).
cDNA synthesis was performed using Qiagen Omniscript RT
Kit, Hilden, Germany (catalogue #205110). Multiplex quantita-
tive real-time PCR assays for the levels of C12orf65 and
RPL13A were performed using SYBR Green PCR Master Mix
Kit (Applied Biosystems) with a Corbett Rotor-Gene real-time
quantitative thermal cycler (Corbett Research/Qiagen). Thermal
cycling and gene-specific primers are available upon request.
Relative quantity of each C12orf65 level was normalised by
RPL13A.
Expression profiling of C12orf65in human Central Nervous
System tissue
Expression data were generated from control human central
nervous system (CNS) tissue using Affymetrix Exon 1.0 STArrays.
CNS samples were collected by the Medical Research Council
Sudden Death Brain and Tissue Bank, Edinburgh, UK,11 and the
Sun Health Research Institute, an affiliate of Sun Health
Corporation, USA.12 A full description of the samples used and
the methods of RNA isolation and processing can be found in
Trabzuni et al,13 and Trabzuni et al.14 All arrays were preprocessed
with robust multiarray average quantile normalisation with GC
background correction15 and log2 transformation in Partek’s
Genomics Suite V.6.6 (Partek, St. Louis, Missouri, USA). Regional
differences in gene-level expression were investigated with Partek’s
mixed-model ANOVA is the name for a statistical test, and gender
and batch effects (date of hybridisation and brain bank) were
included as cofactors.
Blue native in-gel complex V assay
The mitochondrial fraction was obtained from the lymphoblas-
toid cell pellets (7.5×105 cells) using two low-speed centrifuga-
tion steps (600 g×10 min) at 4°C, separated by a homogenisation
step. Then, the mitochondrial membranes were solubilised with a
750 mM amino hexanoic acid/50 mM Bis Tris buffer + 4%
n-dodecyl β-D maltoside detergent. Samples were left on ice for
30 min and a further high spin (14 000 g×10 min) was used to
pellet insoluble material. An equal quantity of mitochondrial
protein was loaded from each sample. Blue Native (BN) gel was
run as previously described,16 using a 3–12% Bis–Tris gel
(Invitrogen) to ensure discrete separation of complex V. Complex
V activity was measured in a reverse direction. Complex V assay
was performed by incubating the gel overnight in stain contain-
ing 34 mM Tris, 270 mM glycine, 14 mM magnesium chloride,
6 mM lead (II) nitrate and 8 mM ATP.
O2 consumption
To measure mitochondrial respiration rate in intact cells,
approximately 1×107 cells were suspended in respiration
medium (HBSS with 10 mM D-glucose) in a Clark-type oxygen
electrode thermostatically maintained at 37°C. The oxygen elec-
trode was calibrated with air-saturated water, assuming
406 nmol O2 atoms/mL at 37°C. Oxygen consumption was
measured over 10 min with addition of oligomycin (final con-
centration 2 μg/mL) and FCCP (0.5 μM). All data were obtained
using an Oxygraph Plus System (Hansatech Instruments, UK)
with chart recording software.
For measurements of mitochondrial membrane potential
(Δψm), cells were loaded with 25 nM tetramethylrhodamine
methylester (TMRM) for 30 min at room temperature in HBSS
(156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4,
2 mM CaCl2, 10 mM glucose and 10 mM HEPES, pH adjusted
to 7.35), and the dye was present during the experiment.
TMRM is used in the redistribution mode and therefore a
reduction in TMRM fluorescence represents Δψm depolarisa-
tion. Z-stack images were obtained for accurate analysis. The
values for wild-type (WT) were set to 100% and the other gen-
otypes were expressed relative to WT17
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Confocal images were obtained using a Zeiss 710 LSM with a
40× oil immersion objective. TMRM was excited using the
560 nm laser and fluorescence was measured at 580 nm.
RESULTS
Clinical details
Three members of a large consanguineous Indian family (figure 1A),
affected by axonal neuropathy (table 1) and optic atrophy, were
identified at the London Royal Free Hospital. Case 3 was first
seen at the age of 35 years and then again at the age of 51 years.
She is the first cousin of Cases 1 and 2 and presented as a child
with delayed milestones, later at the age of 9 years she had lower
limb and at 11 years upper limb weakness, along with static cog-
nitive problems and visual difficulties. The examinations at the
age of 35 and 51 years were remarkably similar with only mild
deterioration of her clinical features. She had no dysmorphic fea-
tures, but severe bilateral optic atrophy and static but significant
cognitive problems. She had a brisk jaw jerk and a pout reflex.
Marked distal symmetrical weakness and wasting affecting the
limbs. In contrast to her cousins, tone in her upper and lower
limbs was reduced with severe distal weakness in upper and
lower limbs. Upper limb reflexes were normal. Knee and
adductor reflexes were abnormally brisk. Ankle and plantar
reflexes were absent. She had a moderately severe thoracic scoli-
osis. Sensation was impossible to assess reliably due to cognition
but was likely to be abnormal. As a crude estimate of visual
acuity, they were able to watch television and recognise faces
across the room and she could do needlework.
Case 1 noted distal wasting and weakness at the age of 8,
which slowly spread proximally. When he was examined (at the
age of 34), he had severe muscle wasting of lower and upper
limbs, bilateral optic atrophy and macular colloid bodies.
Pyramidal signs were present in the upper limbs. Case 3 pre-
sented with a similar syndrome characterised by a very slowly
progressing axonal neuropathy (onset in childhood), bilateral
optic atrophy and pyramidal signs. This CMT6 family was ori-
ginally reported as a case report in 1987 when the family
members were in their middle 30s.14
Nerve biopsy
Light microscopy analysis of sural nerve biopsy from Case 1
showed a marked reduction in large myelinated fibres. The fasci-
cles were populated by numerous small myelinated fibres, the
majority of which were associated with regeneration clusters.
Ultrastructural assessment confirmed the absence of both active
and chronic demyelination and showed no evidence of ongoing
axonal degeneration. The remaining myelinated fibres revealed
normal thickness and morphology of the myelin. Loss of
unmyelinated fibres was indirectly confirmed by increased
amounts of endoneural collagen with the formation of collagen
pockets among flattened Schwann cell profiles (figure 2).
Figure 1 Pedigree of the family and the C12orf65 p.V116X mutation.
(A) Pedigree of the family. A square represents a male person and a
circle represents a female person. A double horizontal line indicates
parental consanguinity. Black symbols indicate affected members with
Charcot–Marie Tooth type 2 (CMT2) and optic atrophy in whom a
neurological exam was performed; blank symbols show unaffected
family members. A diagonal line marks deceased individuals. This
pedigree has been reported elsewhere.25 (B) Upper panel:
whole-exome sequencing data for the p.V116X mutation in C12orf65.
The aligned reads viewed through the Integrative Genomics Viewer
(IGV) viewer (http://www.broadinstitute.org/igv/). Reads are depicted as
arrows (grey bands). A coverage histogram per base is shown above
the reads. RefSeq gene (over the C12orf65 gene) is represented in the
lower part both as amino acid sequence (blue) and as reference
sequence: green, A; orange, G; red, T; blue, C. Dashes represent the
deleted base. Note the drop of coverage (black arrow) over the dashed
base, representing the G base deleted in both samples. (C) Schematic
diagram of the C12orf65 gene and protein. The position of the
mutation in the patient DNA and the position of the resulting
premature stop codon are indicated in red; blue indicates the mutation
and the position of the resulting stop codon described in patients with
severe encephalomyopathy.
Table 1 Nerve conduction studies
Case 1 Case 2 Case 3 V-1 IV-II
SAP amplitude (uV):
Median 10 NA 15 40 NA
Ulnar 6 NA 12 20 16
Sural 2 NA 5 NA NA
MCV (m/s):
Ulnar 41 46 51 54 60
NA, not available; SAP, sensory action potentials, median and ulnar SAPs were
recorded from second and fifth fingers to wrist; MCV, motor conduction velocity,
recorded over abductor digiti minimi (Case 1, V-1 and IV-II) and flexor carpi ulnaris
(Cases 2 and 3).
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Genetic analyses
Autozygosity mapping on two affected cousins (Case 1 and
Case 3) identified five homozygous chromosomal segments
(>1 Mb), concordant in both cousins encompassing 15.8 Mb
and containing 226 genes (NCBI build 37.2). Whole-exome
sequencing was used to perform a comprehensive search for
pathogenic mutations in both cousins. The target region was
sequenced at an average sequence depth of 26.6 for all samples.
To identify potential causal variants, we selected all coding var-
iants in the homozygous regions present in both samples. Then,
Figure 2 Sural nerve biopsies in affected case. Sural nerve biopsies (light and electron microscopy). Case 1. Semithin resin section stained with
toluidine blue (A and B) shows markedly reduced numbers of large myelinated fibres accompanied by numerous small myelinated fibres mainly
associated with regeneration clusters (arrow in B). Ultrastructural assessment (C and D) further highlights frequent regeneration clusters (arrow in C).
The evidence of decreased numbers of unmyelinated fibres is confirmed by increased amounts of endoneural collagen and the formation of collagen
pockets (red arrowhead in D) among flattened Schwann cell profiles (blue arrowhead in D). Scale bar: 60 μm (A), 30 μm (B) and 2 μm (C and D).
Patient with MFN2 mutation. Semithin resin section stained with toluidine blue (A and B) shows markedly reduced numbers of large myelinated
fibres accompanied by occasional regeneration clusters and occasional fibres surrounded by concentric Schwann cell profiles forming onion bulb-like
structures (arrows in B). Ultrastructural assessment (C and D) confirms that myelinated fibres are markedly reduced in numbers and shows no
evidence of active or chronic demyelination; instead it reveals pseudo-onion bulbs indicative of regeneration (arrow in C). The depicted mitochondria
on the transverse sections of the nerve fascicles show no obvious ultrastructural abnormality, although some intra-axonal clusters of mitochondria
are occasionally observed (arrowhead in C). Scale bar: 80 μm (A), 40 μm (B) and 5 μm (C and D). Patient with no known mutation. Semithin resin
section stained with methylene blue azure-basic fuchsin (MBA-BF) (A) shows markedly reduced numbers of large myelinated fibres with no apparent
evidence of regeneration and no evidence of active macrophage-associated demyelination or chronic demyelinating/remyelinating process. Electron
microscopy (B, C and D) confirms the markedly reduced numbers of large and small myelinated fibres (arrows in B and C). The unmyelinated fibres
in contrast are better preserved (arrowhead in D). Scale bar: 40 μm (A) and 5 μm (B, C and D).
Figure 3 Expression of C12orf65 in 12 central nervous system (CNS) regions. (A) Box plot of C12orf65 mRNA expression levels in 12 CNS regions.
The expression levels are based on exon array experiments and are plotted on a log2 scale (y axis). This plot shows significant variation in C12orf65
transcript expression across the 12 CNS regions analysed: putamen (PUTM, n=121), frontal cortex (FCTX, n=122), temporal cortex (TCTX, n=114),
hippocampus (HIPP, n=114), cervical spinal cord (SPCO, n=13), substantia nigra (SNIG, n=96), hypothalamus (HYPO, n=13), medulla (specifically
inferior olivary nucleus, MEDU, n=109), intralobular white matter (WHMT, n=120), thalamus (THAL, n=107) and cerebellar cortex (CRBL, n=129).
Whiskers extend from the box to 1.5× the IQR.
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we filtered them by discarding (i) variants documented in the
dbSNP and the 1000-Genomes Project and (ii) synonymous sub-
stitutions. Five variants passed these filters: two were missense,
one was a non-frameshift deletion and one was a nonsense
mutation. The latter is a 1 bp deletion in C12orf65 gene, result-
ing in a premature stop codon (NM_001143905: c.346delG:
p.V116X) (figure 1B). As mutations in C12orf65 have been
recently described to cause a severe encephalomyopathy17 as
well as spastic paraplegia and optic atrophy,18 we assessed segre-
gation of this mutation in the family. The deletion was homozy-
gous in the affected cases, and either absent or heterozygous in
the unaffected relatives (figure 3). To further investigate the
presence of the mutation in patients with complex neuropathy,
we sequenced the coding exons of C12orf65 in an additional
cohort of 183 patients. None of the patients harboured poten-
tially pathogenic variants.
To determine whether the truncating mutation induced
mRNA nonsense-mediated decay, we tested the level of expres-
sion of C12orf65. This analysis showed that level of the
C12orf65 mRNA was not reduced in the patients’ cells versus
controls (data not shown).
C12orf65 is a nuclear gene that encodes a mitochondrial
matrix protein that appears to contribute to mitochondrial
translation. Nonsense mutations in this have been found in
patients with a mitochondrial disease associated with combined
oxidative phosphorylation enzyme (OXPHOS) deficiency.17
Patients’ cells were analysed by BN-PAGE analysis to study mito-
chondrial respiratory chain protein complexes. This analysis
showed a decreased activity of complex V as well as a defect in
assembly and stability of complex V in the patient sample com-
pared with controls (figure 4A).
In order to investigate the effect of mutations on mitochondrial
respiration, we measured the rate of oxygen consumption in lym-
phocytes. The basal oxygen consumption in Case 3 cells was sig-
nificantly reduced compared with control cells. Oligomycin
(inhibitor of complex V) inhibited the respiration in control lym-
phocytes but to a significantly lesser extent in patients’ cells
(p<0.001; figure 4B), confirming the decreased activity of
complex V in Case 3 cells. Addition of 1 μM of the uncoupler
FCCP accelerated respiration to maximal levels in control lympho-
cytes but to a significantly lesser degree in Case 3 cells, suggesting
that the activity of the respiratory chain in these cells is limited.
Mitochondrial membrane potential (Δψm) is a major indicator
of mitochondrial function and health. Δψm in Case 3 and control
lymphoblasts was assessed by the fluorescent indicator tetra-
methylrhodamine methyl ester, TMRM. Case 3 cells were asso-
ciated with a significant reduction in the TMRM signal (and hence
in Δψm) compared with controls. There were no differences
between cell groups in mitochondrial morphology (figure 4C).
DISCUSSION
The present study describes a novel homozygous mutation in
the C12orf65 gene in patients with neuropathy and optic
atrophy consistent with slowly progressive CMT6. The clinical
phenotype is similar to the other CMT6 family members
reported, but there are additional cognitive features and the
disease is more slowly progressive with family members living a
likely normal lifespan. Mutations in C12orf65 have been previ-
ously described in children with Leigh syndrome, optic atrophy
and ophthalmoplegia,17 as well as in patients with SPG55,18
also characterised by neuropathy and optic atrophy, but as
opposed to the cases presented here they had no cognitive
impairment and a less severe phenotype.
These data suggest a genotype–phenotype correlation, where
the mutation site correlates with disease severity. Indeed
C12orf65 encodes for a 166 amino acid protein involved in
protein translation termination and contains one RF-1 domain,
Figure 4 Mitochondria impairment in the patient’s lymphoblasts.
(A) BN-PAGE (in gel activity) shows reduced complex V activity in Case
3 compared with controls in lymphoblasts (demonstrated by reduced
band density). V (F1-Fo)=complex V holeoenzyme; F1=catalytic site of
complex V only. (B) Oxygen consumption in Case 3 and controls.
Oxygen consumption was measured in immortalised lymphocytes using
a Clark oxygen electrode. Respiration was inhibited by blocking ATP
production using oligomycin (2 μg/mL) and maximised by adding the
uncoupler FCCP (1 μM). Data are represented as mean±SEM. (C) and
(D) Mitochondrial membrane potential. Mitochondrial membrane
potential in control, carrier and Case 3 lymphoblasts was determined
by tetramethylrhodamine methylester (TMRM) fluorescence. Control
was taken as 100%. On the x-axes, C = controls; P = patient.
**indicates p<0.01 compared to wild-type values.
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found also in peptide chain release factors (figure 1C). The
patients with a severe infanthood encephalomyopathy and death
as a child carry mutations in C12orf65 interrupting the RF-1
domain (p.L84X).17 Conversely, mutations sparing the RF-1
domain seem to cause a milder phenotype as reported in the
cases presented here as well as in the SPG55 cases. Of note, the
mutation site in our cases (p.V116X) would suggest a shorter
protein as opposed to the SPG55 cases (p.R132X) and therefore
a more severe phenotype.
We also investigated mitochondrial function in patient cell
lines and showed that this was impaired at multiple levels of
mitochondrial function. Mitochondrial membrane potential as
well as mitochondrial respiration rate were reduced; BN gel ana-
lysis showed a decrease in complex V activity as well as a defect
in the assembly of the complex.
These results highlight the importance of mitochondrial dys-
function in peripheral nerve disease and in optic atrophy. In per-
ipheral nerve disease, the mitochondrial dysfunction is
frequently associated with axonal CMT2. Indeed Mitofusin 2,
the major cause of dominant CMT2, is a mitochondrial mem-
brane protein involved in mitochondrial fusion19 and in the
regulation of mitochondrial membrane potential and the
OXPHOS system.20 Furthermore mutations in GDAP1, which
encodes a mitochondrial membrane protein, and mutations in
MT-ATP6, which encodes the ATP6 subunit of the mitochon-
drial ATP synthase (OXPHOS Complex V), as a cause of CMT2
further highlight the role of the mitochondria in the peripheral
nerve axon.21 Similarly, the most common inherited optic neu-
ropathies, Leber hereditary optic neuropathy (LHON) and auto-
somal dominant optic atrophy, are the result of mitochondrial
dysfunction. LHON is caused by primary mitochondrial DNA
(mtDNA) mutations affecting the respiratory chain complexes,22
while the majority of optic atrophy families have mutations in
the OPA1 gene, which encodes for an inner mitochondrial
membrane protein important for mtDNA maintenance and oxi-
dative phosphorylation.23 24
Although we could not assess the activities of the mitochon-
drial respiratory chain complex c, II–III and IV, the decrease in
mitochondrial respiration rate and the reduction in mitochon-
drial membrane potential point to a global and uniform mito-
chondrial respiration dysfunction, consistent with other reports
describing loss of function mutations in C12orf65 gene.17
CMT6 is a combination of two clinical processes caused by
defective mitochondrial function that leads to axonal neur-
opathy and optic atrophy. The three genes identified in CMT6
confirm this and the phenotype is variable, a frequent finding in
mitochondrial disorders. Overall CMT highlights the link
between the axon and mitochondrial dysfunction and suggested
that this process is likely to be affected in other forms of
acquired axonal dysfunction such as multiple sclerosis and idio-
pathic neuropathy. From a genetic perspective, the combination
of axonal neuropathy and CMT in any patient should alert the
clinician to the possibility of a mitochondrial defect with a clear
list of candidate genes to investigate.
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